SavedAdd your journal

Journals / EMU Journal of Pharmaceutical Sciences / 2025 / Volume: 8 Issue: 3

Chemotherapy and Personalized Medicine: New Approaches in Modern Cancer Treatment

İmge Kunter(Doğu Akdeniz Üniversitesi)
Pages
—
Publication Date
2025-12-26
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review summarizes the basic concepts of tumor biology and chemotherapy and discusses how personalized medicine and precision oncology are changing cancer treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Chemotherapy has been an important part of cancer treatment for many years.
📊
Key Findings & Data:However, its efficacy is often limited because conventional chemotherapy can cause serious side effects and lead to differences in treatment response between patients.
💡
Conclusion & Impact:This review summarizes the basic concepts of tumor biology and chemotherapy and discusses how personalized medicine and precision oncology are changing cancer treatment.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Chemotherapy · Personalized Medicine · Pharmacogenomics

Abstract

Chemotherapy has been an important part of cancer treatment for many years. However, its efficacy is often limited because conventional chemotherapy can cause serious side effects and lead to differences in treatment response between patients. At this point, personalized medicine offers a new approach to eliminating these problems in cancer treatment. Personalized medicine proposes organizing treatment according to the genetic and molecular characteristics of both the tumor and the patient with tailored treatment regimens. Through molecular profiling of the patient and the tumor, oncologists can have a preliminary idea about the most effective drug, allowing them to adjust the treatment specifically for the individual and minimize the harmful effects on healthy tissues. Advances in genomics and precision oncology, and also new platforms such as organoids and organ-on-chips, have made it possible to select drugs, based on tumor-specific biomarkers, genomic alterations, and pharmacogenomic variants. However, there are still some challenges in applying personalized chemotherapy. The main reasons are concerns about the reliability of biomarkers, integration of genomic data into clinical practice, cost-effectiveness, and ethical issues related to genetic privacy. This review summarizes the basic concepts of tumor biology and chemotherapy and discusses how personalized medicine and precision oncology are changing cancer treatment.

🔖

Cite This Article

Kunter, İ. (2025). Chemotherapy and Personalized Medicine: New Approaches in Modern Cancer Treatment. EMU Journal of Pharmaceutical Sciences, Volume: 8 Issue: 3. https://doi.org/10.54994/emujpharmsci.1836760

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (33)

  1. Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, et al. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103(2): 210–216.
  2. Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, et al. (2022). Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis 10(4): 1367–1401.
  3. Bartolomucci A, Nobrega M, Ferrier T, et al. (2025). Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. NPJ Precis Oncol 9: 84.
  4. Batlle E, Clevers H (2017). Cancer stem cells revisited. Nat Med 23(10): 1124–1134.
  5. Castillo DR, Guo M, Shah P, et al. (2025). CLDN18.2 and PD-L1 profiling in gastric cancer. Transl Oncol 28: 101065.
  6. Chitrangi S, Vaity P, Jamdar A, Bhatt S (2023). Patient-derived organoids for precision oncology: A platform to facilitate clinical decision making. BMC Cancer 23: 689.
  7. de With M, van Doorn L, Kloet E, van Veggel A, Matic M, et al. (2023). Irinotecan-induced toxicity: A pharmacogenetic study beyond UGT1A1. Clin Pharmacokinet 62: 1589–1597.
  8. Emran TB, Shahriar A, Mahmud AR, Rahman T, Abir MH, et al. (2022). Multidrug resistance in cancer: Understanding molecular mechanisms, immunoprevention and therapeutic approaches. Front Oncol 12: 891652.
  9. Fan S, Qingyu M, Zhao Z, Niu W (2025). Long-term response in rare MSI-H CRC with BRAF mutation. Front Immunol 16: 1698410.
  10. Ghoreyshi N, Heidari R, Farhadi A, Chamanara M, Farahani N, et al. (2025). Next-generation sequencing in cancer diagnosis and treatment: Clinical applications and future directions. Discov Oncol 16(1): 578.
  11. Grodzka A, Knopik-Skrocka A, Kowalska K, Kurzawa P, Krzyżaniak M, et al. (2023). Molecular alterations of driver genes in non-small cell lung cancer: From diagnostics to targeted therapy. EXCLI J 22: 415–432.
  12. Hanahan D (2022). Hallmarks of cancer: New dimensions. Cancer Discov 12(1): 31–46.
  13. Jin H, Yang Y, Yan C, Liu M, Heet X, et al. (2025). Tumor immunophenotyping in HER2+ breast cancer. Mol Cancer 24: 483.
  14. Kaufman NEM, Dhingra S, Jois SD, Vicente MGH (2021). Molecular targeting of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). Molecules 26(4): 1076.
  15. Kim C, Gao R, Sei E, Brandt R, Hartman J, et al. (2018). Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell 173(4): 879–893.e13.
  16. Kim J, Koo BK, Knoblich JA (2020). Human organoids: Model systems for human biology and medicine. Nat Rev Mol Cell Biol 21: 571–584.
  17. Klug M, Kirshenboim Z, Truong MT, Sorin V, Keren Gilat E, et al. (2025). The ninth edition TNM staging system for thymic epithelial tumors: A comprehensive review. Radiol Cardiothorac Imaging 7(5).
  18. Li R, Liu X, Huang X, Zhang D, Chen Z, et al. (2024). Single-cell transcriptomic analysis deciphers heterogenous cancer stem-like cells in colorectal cancer and their organ-specific metastasis. Gut 73(3): 470–484.
  19. Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL (2020). Molecular profiling for precision cancer therapies. Genome Med 12(1): 8.
  20. Martin de la Fuente L, Westbom-Fremer S, Arildsen NS, Hartman L, Malander S, et al. (2020). PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma. Virchows Arch 477(1): 83–91.
  21. Mohan N, Luo X, Shen Y, Olson Z, Agrawal A, et al. (2021). A novel bispecific antibody targeting EGFR and VEGFR2 is effective against triple negative breast cancer via multiple mechanisms of action. Cancers 13(5): 1027.
  22. Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, et al. (2018). Maintenance olaparib in newly diagnosed advanced ovarian cancer. N Engl J Med 379(26): 2495–2505.
  23. Pernik MN, Bird CE, Traylor JI, Shi DD, Richardson TE, et al. (2021). Patient-derived cancer organoids for precision oncology treatment. J Pers Med 11(5): 423.
  24. Ren X, Huang M, Weng W, Xie Y, Wu Y, et al. (2023). Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application. Cell Rep Med 4(11): 101277.
  25. Qiao D, Wang RC, Wang Z (2025). Precision oncology: Current landscape, emerging trends, challenges, and future perspectives. Cells 14(22): 1804.
  26. Relling MV, Evans WE (2015). Pharmacogenomics in the clinic. Nature 526(7573): 343–350.
  27. Tilsed CM, Fisher SA, Nowak AK, Lake RA, Lesterhuis WJ (2022). Cancer chemotherapy: Insights into cellular and tumor microenvironmental mechanisms. Front Oncol 12: 960317.
  28. Trendowski MR, El Charif O, Dinh PC, Wheeler HE, Ardeshir-Rouhani-Fard S, et al. (2019). Genetic and modifiable risk factors contributing to cisplatin-induced toxicities. Clin Cancer Res 25(4): 1147–1155.
  29. Wang W, Gao M, Gao Y, Zheng H, Song N, et al. (2025). Integrating homologous recombination deficiency subtyping with TCGA molecular classification for enhanced prognostic stratification and personalised therapy in endometrial cancer. Br J Cancer.
  30. Yang Z, Carrio-Cordo P, Baudis M (2024). Copy number variation heterogeneity reveals biological inconsistency in hierarchical cancer classifications. Mol Cytogenet 17: 26.
  31. Yi K, Park SH, Kim DU, Jeon DY, Lee HJ, et al. (2023). Patient-derived organoid model for predicting the chemoresponse in patients with colorectal cancer. In Vivo 37(4): 1751–1759.
  32. Zazuli Z, Vijverberg S, Slob E, Liu G, Carleton B, et al. (2018). Genetic variations and cisplatin nephrotoxicity: A systematic review. Front Pharmacol 9: 1111.
  33. Zhao L, Song L, Wang H, Tian W, Xi J, et al. (2025). Post-translational modification gene signature for treatment response in breast cancer. Sci Rep 15: 23772.